Extracellular Fluid/Intracellular Fluid Volume Ratio as a Novel Risk Indicator for All-Cause Mortality and Cardiovascular Disease in Hemodialysis Patients

Eun-Jung Kim1,2, Myung-Jin Choi1, Jeoung-Hwan Lee1, Ji-Eun Oh1, Jang-Won Seo1,2, Young-Ki Lee1, Jong-Woo Yoon1, Hyung-Jik Kim1, Jung-Woo Noh1, Ja-Ryong Koo1,2*

1 Department of Internal Medicine, Hallym Kidney Research Institute, College of Medicine, Hallym University, Chuncheon, Korea, 2 Division of Nephrology, Dongtan Sacred Heart Hospital, Hallym University Medical Center, Hwaseong-si, Korea

* jrkoo@hallym.ac.kr

Abstract

Background

In hemodialysis patients, fluid overload and malnutrition are accompanied by extracellular fluid (ECF) expansion and intracellular fluid (ICF) depletion, respectively. We investigated the relationship between ECF/ICF ratio (as an integrated marker reflecting both fluid overload and malnutrition) and survival and cardiovascular disease (CVD) in the context of malnutrition-inflammation-arteriosclerosis (MIA) complex.

Methods

Seventy-seven patients from a single hemodialysis unit were prospectively enrolled. The ECF/ICF volume was measured by segmental multi-frequency bioimpedance analysis. MIA and volume status were measured by serum albumin, C-reactive protein (CRP), pulse wave velocity (PWV) and plasma B-type natriuretic peptide (BNP), respectively.

Results

The mean ECF/ICF ratio was 0.56±0.06 and the cut-off value for maximum discrimination of survival was 0.57. Compared with the low ECF/ICF group, the high ECF/ICF group (ratio≥0.57, 42%) had higher all-cause mortality, CVD, CRP, PWV, and BNP, but lower serum albumin. During the 5-year follow-up, 24 all-cause mortality and 38 CVD occurred (18 and 24, respectively, in the high ECF/ICF group versus 6 and 14 respectively in the low ECF/ICF group, P<0.001). In the adjusted Cox analysis, the ECF/ICF ratio nullifies the effects of the MIA and volume status on survival and CVD and was an independent predictor of all-cause mortality and CVD: hazard ratio (95% confidence interval); 1.12 (1.01–1.25) and 1.09 (1.01–1.18) for a 0.01 increase in the ECF/ICF ratio. The degree of malnutrition (albumin), inflammation (CRP), arteriosclerosis (PWV), and fluid overload (BNP) were correlated well with the ECF/ICF ratio.
Conclusions
Hemodialysis patients with high ECF/ICF ratio are not only fluid overloaded, but malnourished and have stiff artery with more inflammation. The ECF/ICF ratio is highly related to the MIA complex, and is a major risk indicator for all-cause mortality and CVD.

Introduction
For a long time, fluid overload and malnutrition have been known to be major risk factors for morbidity and mortality in chronic hemodialysis patients [1–3]. Recently, a strong association between malnutrition, inflammation, and arteriosclerosis/atherosclerosis (the so-called MIA syndrome) have been described and proposed as the main causes of morbidity and mortality in chronic hemodialysis patients [1, 4–6]. Among the MIA components, inflammation seems to play a pivotal role in the pathogenesis of malnutrition and arteriosclerosis by the following mechanisms: (1) inflammatory response is responsible for malnutrition by increased protein catabolism and muscle wasting [4, 6]; and (2) uremic inflammation is known to promote extra-osseous deposition of calcium to vessel walls, resulting in vascular calcification and arteriosclerosis [7].

There are also several supporting data showing the causal relationships between extracellular fluid (ECF) overload and the MIA complex [8–10]. It has been proposed that fluid overload act as an inflammatory stimulus by immune activation resulting from poor tissue perfusion, and bowel edema- induced translocation of bowel endotoxins into the circulation [9]. Fluid overload might also play an important role in the development of arteriosclerosis, through the increase in vessel wall stress caused by arterial distension (Laplace’s law) [10]. Conversely, hypoalbuminemia and increased vascular permeability caused by inflammation will enhance extravascular fluid shift, resulting in ECF volume overload [11]. In addition, malnutrition caused by inflammation could deplete body cell mass, which eventually leads to the decrease in intracellular fluid (ICF) volume, and the relative increase in ECF/ICF volume ratio [12, 13].

It is possible to distinguish between total body fluid (TBW) and ECF with multi-frequency bioimpedance analysis (MF-BIA), by using the resistance of cell membranes to relatively low-frequency currents. At high frequencies, currents flow across both intra- and extracellular spaces; however, at low frequencies, currents flow mainly through extracellular space; allowing the assessment of ECF, ICF, and TBW [14].

In view of the above considerations, the ECF/ICF ratio measured by MF-BIA may be highly related to the MIA complex, and could be defined as a novel integrated marker reflecting both fluid overload and malnutrition (Fig 1). In this study, we investigated the relationship of ECF/ICF ratio to survival and cardiovascular disease (CVD) in the context of MIA complex in chronic hemodialysis patients.

Materials and Methods
Patients
This study was a single center, prospective, longitudinal study with patients recruited from the hemodialysis unit of Hallym University Hospital (Chuncheon, Korea). The protocol of this study was approved by the Institutional Review Board of Hallym University Hospital (Chuncheon, Korea) and all patients provided written informed consent. Patients were eligible for inclusion if they (1) had been on hemodialysis for at least 6 months, (2) had no clinical CVD for 3 months preceding enrollment, (3) were 18 years of age or older, and (4) agreed to participate in the follow-up study. Patients who underwent renal transplantation and patients...
who moved were censored on the day of transplantation or departure. Among the 86 eligible hemodialysis patients, 77 patients were prospectively enrolled in the study from January 2007 and followed up for 5 years. Nine patients were excluded based on the exclusion criteria, namely patients with an underlying malignancy, Child’s C liver cirrhosis or patients with incomplete data. During the follow-up period, 8 patients were censored due to renal transplantation (n = 4) and transfer to other hemodialysis unit (n = 4). The causes of chronic renal failure were diabetic nephropathy in 29 patients (37.7%), chronic glomerulonephritis in 25 patients (32.5%), hypertension in 17 patients (22.1%), and polycystic kidney disease in 1 patient (1.3%). The remainder was attributed to unknown and/or miscellaneous causes. All participating patients underwent three 4-hour sessions of hemodialysis per week using bicarbonate-buffered dialysate. The dialysis membrane used for all patients was composed of polysulfone (Fresenius F6HPS; Fresenius, Bad Homburg, Germany), with a surface area of 1.3 m$^2$. All the biochemical measurements and assessments of fluid volume, MIA component and cardiovascular function were performed at mid-week (Wednesday or Thursday) after a short (1 day) inter-dialytic interval.

Assessments of fluid volume and MIA components

The ECF, ICF, and TBF volumes were measured by segmental MF-BIA, which was performed 30 minutes before hemodialysis with the subject in the standing position. Plasma B-type natriuretic peptide (BNP) was also measured to evaluate the fluid volume status.

---

**Fig 1. The possible relationship between the MIA complex and ECF/ICF volumes.** As an integrated marker of fluid volume overload and malnutrition, the ECF/ICF ratio might be highly-related to the MIA complex, and can be a major risk indicator of morbidity and mortality in chronic hemodialysis patients.

doi:10.1371/journal.pone.0170272.g001
Among the MIA components, the severity of malnutrition (the first MIA component) was assessed by the mean value of pre-dialysis serum albumin levels, which were measured three times at weekly intervals. The modified subjective global assessment (SGA) used in the Canada-USA Peritoneal Dialysis Study [15] was also used to evaluate the overall protein-energy nutritional status. SGA includes four items (weight loss over the past 6 months, anorexia, subcutaneous fat, and muscle mass) scored on a seven-point Likert scale. Scores of 1 to 2 represent severe malnutrition; 3 to 5, moderate to mild malnutrition; and 6 to 7, normal nutrition. The normalized protein catabolic rate (nPCR) was calculated as a marker of protein intake, by using a variable-volume single-pool urea kinetic calculator on a web site (Hypertension Dialysis Clinical Nephrology; http://www.hdcn.com/).

The degree of an inflammatory reaction (the second MIA component) was assessed by a mean value of serum C-reactive protein (CRP) levels, which were also measured three times at weekly intervals.

Pre-dialysis brachial-ankle pulse wave velocity (PWV) was measured as an indicator of arteriosclerosis (the third MIA component), using a volume plethysmographic apparatus (Form/ABI, Colin, Co. Ltd., Komaki, Japan). Details of the methodology were described elsewhere [16]. Each subject was examined while resting in the supine position. Cuffs were wrapped on both the brachia and ankles. Pulse volume waveforms at the brachium and ankle were recorded using a semiconductor pressure sensor. Brachial-ankle PWV was measured after at least 5 minutes of rest.

Segmental MF-BIA

In this study, we used segmental MF-BIA, which measured the resistance of the trunk or each limb separately. It is a more appropriate approach to monitor body water during hemodialysis than whole-body BIA, as changes in local resistance can be allocated to segments with uniformed geometry and resistivity [17]. Water volumes were calculated by means of a population-based regression equation using the impedance index (height squared/resistance).

Eight stainless steel tactile electrodes were used to measure the segmental impedance of the trunk and extremity using Inbody2.0 (Biospace Co, Seoul, Korea), as described in our previous study [18]. Two electrodes were in contact with the palm and thumb of each hand, while another two with the anterior and posterior aspects of the sole of each foot. Impedance was measured at frequencies of 5, 50, 250, and 500 kHz in the standing position. The validity of the method has been reported using sodium bromide and deuterium oxide dilutions [14].

To decrease operator variability, all MF-BIA tests were performed by the same operator, trained in MF-BIA study. Measurements were taken using same equipment, room, and temperature, in the same position.

Echocardiography, ankle-brachial index and biochemical analysis

Echocardiography was performed 30 min prior to hemodialysis by a single experienced cardiologist who was blinded to the patients’ clinical and laboratory data. The ejection fraction and left ventricular mass index (LVMI) were measured according to the recommendations of the American Society of Echocardiography [19].

As a surrogate marker of atherosclerotic peripheral arterial disease, pre-dialytic ankle brachial index (ABI) was measured using Omron VP-1000 Vascular Profiler (Colin, Co. Ltd., Komaki, Japan).

Blood samples for biochemical analysis were obtained from the patient’s arteriovenous access or tunneled dialysis catheter before hemodialysis. Serum CRP level was determined using a particle enhanced immunoturbidimetric assay (Roche diagnostics, USA). Plasma B-
type natriuretic peptide (BNP) concentration was determined using the ADVIA Centaur® BNP immunoassay on the ADVIA Centaur analyzer (Siemens Healthcare Diagnostics Inc., Deerfield, IL, USA). Plasma intact-parathyroid hormone (PTH) was measured using an immunochemiluminometric assay on the ADVIA Centaur analyzer (Siemens Healthcare Diagnostics Inc., Deerfield, IL, USA). Urea, albumin, hemoglobin, calcium, phosphate and total CO₂ were measured by standard techniques. Each measurement was repeated three times at weekly intervals; the mean value derived was then used for statistical analysis.

Outcomes
The primary endpoint was time to all-cause mortality. The secondary endpoint was time to fatal and non-fatal cardiovascular events requiring admission. Cardiovascular events were defined as ischemic heart disease, congestive heart failure, stroke, and peripheral vascular disease. The diagnosis of ischemic heart disease was based on the clinical history, electrocardiograms, stress test, cardiac biomarker (troponin I), and coronary angiography. The diagnosis of congestive heart failure was determined by the clinical history and echocardiography. Stroke was identified by clinical signs of neurological dysfunction and abnormalities in brain imaging studies. Symptomatic peripheral vascular disease was determined from ABI, CT, and percutaneous angiography. Hemodialysis vascular access dysfunction was not included as an outcome measure.

Statistical analysis
Data analysis was performed using the SPSS 17.0 software package (SSPS Inc., Chicago, IL, USA). Data measured only at enrollment were used for analysis; although, biochemical measurement was repeated three times at weekly intervals and the mean value was used for statistical analysis to minimize the inter-dialytic variability, it also represents data at enrollment (during 1st 3 weeks) and no follow-up variable was included in the analysis.

All data are expressed as mean ± SD and a P value of <0.05 was considered statistically significant. The Kolmogorov-Smirnov test was used to verify the normality of the distribution of continuous variables. Variables that did not show normal distribution were serum CRP, plasma BNP and intact PTH levels, which were expressed as median and interquartile range (IQR). Nonparametric comparison and correlation tests were used for these variables. The differences between the high and low ECF/ICF ratio groups were assessed using unpaired Student’s t-test, Mann–Whitney U test, and chi-square test. The correlations of the ECF/ICF ratio with MIA components and BNP were assessed using Pearson’s and Spearman’s correlation coefficients. The difference in survival according to the ECF/ICF ratio was estimated using the Kaplan-Meier product-limit method and compared using the Mantel (log-rank) test. The prognostic factors of survival were identified using the univariate and multivariate Cox proportional hazards regression model. Estimated hazard ratios and their 90% confidence intervals were calculated with the estimated regression coefficients and standard errors. For maximum discrimination of survival by ECF/ICF ratio, an ECF/ICF ratio cut-off value was calculated by the maximally selected rank statistics method, available in the R maxstat package (R version 3.3.1, The R foundation for Statistical Computing).

Results
The characteristics of the cohort at the time of inclusion are shown in Table 1. The mean ECF/ICF ratio was 0.56±0.06. During the 5-year follow-up, 24 all-cause mortality and 38 new cardiovascular events occurred. The cut-off ECF/ICF ratio for maximum discrimination of all-cause mortality by survival analysis was 0.57. The comparisons according to the cut-off ECF/
ICF ratio are shown in Table 2. Compared with the low ECF/ICF group (ECF/ICF ratio < 0.57), the high ECF/ICF group (ECF/ICF ratio ≥ 0.57) had higher all-cause mortality, CVD, systolic blood pressure (BP), pulse pressure, number of antihypertensive pills, and LVMI, but lower hemodialysis duration, hemoglobin, BUN, serum creatinine, plasma intact PTH, and serum phosphate. The mean age and proportions of patients with diabetes and prior CVD were also higher in the high ECF/ICF ratio group.

Among the MIA and fluid volume components, serum albumin, SGA score, and nPCR were significantly lower, while serum CRP, PWV, and plasma BNP were significantly higher in the high ECF/ICF ratio group compared with the low ECF/ICF ratio group (Table 3). In correlation analysis between the various fluid volume ratios (ECF/ICF, ECF/dry weight, TBF/dry weight) and the individual MIA components and plasma BNP (Table 4), the ECF/ICF ratio was well correlated with all MIA components and plasma BNP. However the dry weight adjusted sole ECF volume (ECF/dry weight) was correlated only with the SGA score, nPCR, and plasma BNP, while the dry weight adjusted sole TBF volume (TBF/dry weight) was correlated with none of the MIA components and plasma BNP.

Fig 2 shows the Kaplan-Meier curves of all-cause and CVD free survival in the study population according to the cut-off ECF/ICF ratio. A higher ECF/ICF ratio was associated with a significantly lower all-cause and CVD free survival (all-cause mortality and new CVD were 18 and 24, respectively, in the high ECF/ICF ratio group, versus 6 and 14, respectively, in the low ECF/ICF ratio group; log rank P < 0.001).

The results of the unadjusted and adjusted Cox proportional hazard analysis of all-cause mortality and new CVD are listed in Tables 5 and 6. Cox model 1 (Table 5) is composed of the 3 MIA components (i.e., serum albumin, CRP, and PWV), fluid volume marker (plasma BNP), and ECF/ICF ratio. Cox model 2 (Table 6) is composed of the ECF/ICF ratio and other major cardiovascular risk factors in chronic hemodialysis patients.
In the unadjusted univariate Cox model 1, the ECF/ICF ratio, MIA components, and plasma BNP were independent predictors of all-cause mortality. ECF/ICF ratio and MIA components were also independent predictors of new CVD. In the adjusted multivariate Cox model 1, the ECF/ICF ratio is a sole risk factor nullifying the effects of the all 3 MIA components and plasma BNP on all-cause mortality and new CVD.

As the ECF/ICF ratio nullified the effects of the MIA components and plasma BNP on all-cause mortality and new CVD in the adjusted multivariate Cox model 1, the ECF/ICF ratio (instead of individual MIA components and plasma BNP) was included as an integrated risk factor in the final model.

### Table 2. Comparisons according to the cut-off ECF/ICF ratio.

| Variables                              | ECF/ICF<0.57 | ECF/ICF ≥0.57 | P      |
|----------------------------------------|--------------|--------------|--------|
| Number of patients (%) n               | 58 (45)      | 42 (32)      |        |
| All-cause mortality (%) n              | 13.3 (6)     | 56.3 (18)    | <0.001 |
| Cardiac disease                        | 4.4 (2)      | 12.5 (4)     |        |
| Stroke                                 | 4.4 (2)      | 15.6 (5)     |        |
| Infection                              | 2.2 (1)      | 21.9 (7)     |        |
| Undefined                              | 2.2 (1)      | 6.3 (2)      |        |
| New CVD (%) n                          | 31.1 (14)    | 75.0 (24)    | <0.001 |
| Ischemic heart disease                 | 11.1 (5)     | 21.9 (7)     |        |
| Congestive heart failure               | 6.7 (3)      | 28.1 (9)     |        |
| Stroke                                 | 6.7 (3)      | 21.9 (7)     |        |
| Peripheral vascular disease            | 6.7 (3)      | 3.1 (1)      |        |
| Age (years)                            | 49.3±11.5    | 57.3±12.5    | 0.005  |
| Women (%) n                            | 40.0 (18)    | 59.4 (19)    | 0.11   |
| Diabetes mellitus (%) n                | 13.3 (6)     | 71.9 (23)    | <0.001 |
| Prior CVD (%) n                        | 8.9 (4)      | 56.3 (18)    | <0.001 |
| Duration of dialysis (month)           | 57.6±39.8    | 40.0±29.0    | 0.04   |
| Kt/V                                   | 1.58±0.25    | 1.64±0.26    | 0.35   |
| Hemoglobin (g/dL)                      | 9.78±0.89    | 9.30±0.56    | 0.008  |
| BUN (mg/dL)                            | 63.2±12.0    | 53.2±12.6    | 0.002  |
| Serum creatinine (mg/dL)               | 8.93±1.98    | 7.06±1.37    | <0.001 |
| Plasma total CO₂ (mmol/L)              | 17.1±1.7     | 18.10±1.9    | 0.02   |
| Plasma intact PTH (pg/mL)              | 170.0±139.2  | 53.6±72.1    | <0.001*|
| Serum calcium (mg/dL)                  | 8.68±0.76    | 8.77±0.64    | 0.64   |
| Serum phosphate (mg/dL)                | 4.42±1.45    | 3.64±1.01    | 0.03   |
| Ankle brachial index                   | 1.05±0.10    | 1.05±0.19    | 0.95   |
| Pre-dialytic SBP (mmHg)                | 146.9±21.5   | 168.6±21.7   | <0.001 |
| Pre-dialytic DBP (mmHg)                | 85.8±9.0     | 85.6±11.6    | 0.95   |
| Pulse pressure (mmHg)                  | 61.1±16.1    | 83.0±18.1    | <0.001 |
| Number of antihypertensive pills       | 2.25±2.48    | 4.11±2.50    | 0.003  |
| LV ejection fraction (%)               | 69.9±7.7     | 68.4±10.5    | 0.51   |
| LV mass index                          | 109.6±37.2   | 149.3±30.3   | <0.001 |

Note: Data are presented as the mean±SD or as % (n).
*analyzed by Mann–Whitney U test.

Conversion factors for units: creatinine in mg/dL to μmol/L, ×88.4; urea nitrogen in mg/dL to μmol/L, ×0.357; calcium in mg/dL to mmol/L, ×0.249; phosphorus in mg/dL to mmol/L, ×0.3229.

Abbreviations: BNP, brain natriuretic peptide; SBP, systolic blood pressure; DBP, diastolic blood pressure; CRP, C-reactive protein; ECF/ICF, extracellular fluid/intracellular fluid; LV, left ventricular; nPCR, normalized protein catabolic rate; PTH, parathyroid hormone; PWV, pulse wave velocity; SGA, subjective global assessment; BUN, blood urea nitrogen.

doi:10.1371/journal.pone.0170272.t002

In the unadjusted univariate Cox model 1, the ECF/ICF ratio, MIA components, and plasma BNP were independent predictors of all-cause mortality. ECF/ICF ratio and MIA components were also independent predictors of new CVD. In the adjusted multivariate Cox model 1, the ECF/ICF ratio is a sole risk factor nullifying the effects of the all 3 MIA components and plasma BNP on all-cause mortality and new CVD.

As the ECF/ICF ratio nullified the effects of the MIA components and plasma BNP on all-cause mortality and new CVD in the adjusted multivariate Cox model 1, the ECF/ICF ratio (instead of individual MIA components and plasma BNP) was included as an integrated risk factor in the final model.
marker reflecting both the MIA complex and fluid volume status in Cox model 2. In the unadjusted univariate Cox model 2, the ECF/ICF ratio, diabetes, prior CVD, age, systolic BP, and low ankle brachial index were independent predictors of all-cause mortality and new CVD. In the adjusted multivariate Cox model 2 (composed of variables with a P less than 0.05 in the unadjusted univariate Cox model 2), only the ECF/ICF ratio and prior CVD were independent predictors of all-cause mortality and new CVD.

Re-analysis of the adjusted multivariate Cox model 1 by replacing ECF/ICF ratio by ECF/TBF ratio to compare the 2 predictor showed that, like the ECF/ICF ratio, the ECF/TBF ratio is a sole risk factor nullifying the effects of the all 3 MIA components and plasma BNP on all-cause mortality and new CVD: hazard ratio (95% confidence interval): 1.43 (1.07–1.90) and 1.30 (1.05–1.61) for a 0.01 increase in the ECF/TBF ratio. However, contrary to the ECF/ICF ratio, the ECF/TBF ratio was not an independent predictor of all-cause mortality and new CVD: hazard ratio (95% confidence interval): 1.19 (0.83–1.73) and 1.08 (0.84–1.39) for a 0.01 increase in the ECF/TBF ratio.

Discussion

This was the first study to show that the ECF/ICF ratio, as measured by MF-BIA, can be used as a novel risk indicator for all-cause mortality and CVD in chronic hemodialysis patients. In

Table 3. Comparisons of the MIA components and fluid volume status according to the cut-off ECF/ICF ratio.

| Variables       | ECF/ICF<0.57 | ECF/ICF ≥0.57 | P       |
|-----------------|--------------|--------------|---------|
| MIA components  |              |              |         |
| Serum albumin (g/dL) | 3.98±0.26    | 3.70±0.37    | <0.001  |
| SGA score       | 5.58±1.03    | 3.94±1.19    | <0.001  |
| nPCR            | 1.12±0.16    | 1.00±0.15    | 0.003   |
| Serum CRP (mg/L)| 0.95±1.41    | 2.90±3.15    | <0.001* |
| PWV (m/sec)     | 1647±404     | 2288±699     | <0.001  |
| Fluid volume status |            |              |         |
| Plasma BNP (pg/mL) | 372±469      | 1160±1220   | <0.001* |

Note: Data are presented as the mean±SD.

*analyzed by Mann–Whitney U test.

Abbreviations: BNP, brain natriuretic peptide; CRP, C-reactive protein; ECF/ICF, extracellular fluid/intracellular fluid; MIA, malnutrition-inflammation-arteriosclerosis; nPCR, normalized protein catabolic rate; PWV, pulse wave velocity; SGA, subjective global assessment.

doi:10.1371/journal.pone.0170272.t003

Table 4. Correlations (r) between the various fluid volume ratios and the individual MIA components and plasma BNP.

| Fluid volume ratios | MIA components | Plasma BNP |
|---------------------|----------------|------------|
|                     | Serum albumin | SGA score  | nPCR | Serum CRP | PWV | BNP         |
| ECF/ICF             | -0.547a       | -0.674a     | -0.446a | 0.537a     | 0.690a | 0.642b*     |
| ECF/Dry weight      | -0.061        | -0.311c     | -0.309c | 0.127*     | 0.166  | 0.419b*     |
| TBF/Dry weight      | 0.176         | -0.015      | -0.188  | -0.162*    | -0.151 | 0.091*      |

*P<0.001.

bP<0.01.

*cP<0.05.

*analyzed by Spearman’s correlation test.

Abbreviations: BNP, brain natriuretic peptide; CRP, C-reactive protein; ECF/ICF, extracellular fluid/intracellular fluid; MIA, malnutrition-inflammation-arteriosclerosis; nPCR, normalized protein catabolic rate; PWV, pulse wave velocity; SGA, subjective global assessment; TBF, total body fluid.

doi:10.1371/journal.pone.0170272.t004
A higher ECF/ICF ratio (≥0.57) was associated with a significantly lower all-cause and CVD free survival (log rank P<0.001). CVD, cardiovascular disease; ECF/ICF, extracellular fluid/intracellular fluid.

doi:10.1371/journal.pone.0170272.g002
this population of patients, higher ECF volume represents fluid excess, while lower ICF volume represents malnutrition (or low body cell mass) [12,13]. Both chronic fluid overload and malnutrition are well-recognized factors contributing to the high morbidity and mortality in hemodialysis patients. However, there are many confounding interactions between fluid volume and nutritional status in chronic hemodialysis patients, especially in the context of the MIA complex. For example, fluid overload and bowel edema could lead to altered gut permeability to bacteria and/or endotoxins, and the subsequent translocation of these materials into the circulation. Translocated bacteria and/or endotoxins within the circulation could be an important stimulus of systemic immune activation and cytokine production [9]. In chronic hemodialysis patients, fluid overload-induced arterial distension is also associated with increased aortic PWV (Laplace’s law); better management of fluid overload leads to a significant decrease in arterial PWV and stiffness [10, 20]. Conversely, inflammation-induced hypoalbuminemia and increased vascular permeability enhance extravascular fluid shift, thereby resulting in ECF volume overload [11]. It is also well known that inflammatory conditions can cause loss of muscle mass through the activation of the ubiquitin-proteasome proteolytic system [21]. This depletion in body cell mass could eventually lead to a decrease in the ICF volume and a relative increase in the ECF/ICF volume ratio.

In view of the above considerations, the ECF/ICF ratio was postulated to be highly-related to the MIA complex and could be defined as a novel integrated marker reflecting both fluid overload and malnutrition. In this study, the high ECF/ICF ratio group had higher serum CRP, PWV, and plasma BNP, as well as lower serum albumin, nPCR, and SGA score, all of which are MIA and fluid volume components. The ECF/ICF ratio was also found to be well-correlated with all of the MIA and fluid volume components, and nullified the effects of the individual MIA-fluid volume components on all-cause mortality and new CVD in multivariate analysis. As such, the ECF/ICF ratio can be used as an integrated marker reflecting both the MIA complex and fluid volume status in chronic hemodialysis patients.

In this study, a higher ECF/ICF ratio was associated with a significantly higher all-cause mortality and new CVD. The higher ECF/ICF ratio group also had higher systolic BP, pulse pressure, LVMI, and number of ingested anti-hypertensive pills, all of which can also be indirect markers of

### Table 5. Unadjusted univariate and adjusted multivariate Cox proportional hazard model 1 for all-cause mortality and new CVD; Model 1 is composed of the 3 MIA components, fluid volume marker (plasma BNP), and ECF/ICF ratio.

| Risk factors                  | All-cause mortality | New CVD |
|------------------------------|---------------------|---------|
|                              | Hazard Ratio (95% CI) | P       | Hazard Ratio (95% CI) | P       |
| Unadjusted univariate        |                     |         |                     |         |
| Malnutrition (serum albumin, /0.1g/dL) | 0.72 (0.64–0.81) | <0.001  | 0.70 (0.62–0.80) | <0.001  |
| Inflammation (serum CRP, /1mg/L) | 1.36 (1.20–1.53) | <0.001  | 1.47 (1.31–1.66) | <0.001  |
| Arteriosclerosis (PWV, /100m/sec) | 1.14 (1.07–1.20) | <0.001  | 1.18 (1.11–1.25) | <0.001  |
| Volume (Plasma BNP, /100pg/mL) | 1.04 (1.01–1.08) | 0.01    | 1.03 (1.00–1.06) | 0.09    |
| ECF/ICF (/0.01)               | 1.18 (1.11–1.25) | <0.001  | 1.17 (1.11–1.24) | <0.001  |
| Adjusted multivariate        |                     |         |                     |         |
| Malnutrition (serum albumin, /0.1g/dL) | 0.80 (0.63–1.01) | 0.06    | 0.88 (0.73–1.06) | 0.16    |
| Inflammation (serum CRP, /1mg/L) | 1.24 (0.96–1.60) | 0.11    | 1.20 (0.97–1.49) | 0.10    |
| Arteriosclerosis (PWV, /100m/sec) | 0.98 (0.86–1.11) | 0.71    | 1.08 (0.97–1.20) | 0.19    |
| Volume (plasma BNP, /100pg/mL) | 1.03 (0.93–1.13) | 0.61    | 0.99 (0.92–1.07) | 0.76    |
| ECF/ICF (/0.01)               | 1.14 (1.03–1.26) | 0.01    | 1.11 (1.02–1.19) | 0.01    |

Abbreviations: BNP, brain natriuretic peptide; CRP, C-reactive protein; CVD, cardiovascular disease; ECF/ICF, extracellular fluid/intracellular fluid; MIA, malnutrition-inflammation-arteriosclerosis; PWV, pulse wave velocity.

doi:10.1371/journal.pone.0170272.t005
underlying fluid volume excess and vascular stiffness. Furthermore, the mean age and proportions of patients with diabetes and prior CVD were also higher in the higher ECF/ICF ratio group. These results suggest that in elderly patients with diabetes and prior CVD, specific attention for the possible presence of fluid overload and malnutrition are highly required.

In the unadjusted univariate Cox analysis, many traditional and non-traditional risk factors such as MIA components, fluid volume marker, diabetes, age, systolic BP, and ankle brachial index were significant risk factors for all-cause mortality and new CVD. However, in adjusted multivariate Cox analysis, only the ECF/ICF ratio and prior CVD were significant risk factors for both all-cause mortality and new CVD, which again underlies the importance and clinical utility of the ECF/ICF ratio as an integrative and universal risk indicator in chronic hemodialysis patients.

| Table 6. Unadjusted univariate and adjusted multivariate Cox proportional hazard model 2 for all-cause mortality and new CVD. In model 2, with other major cardiovascular risk factors, the ECF/ICF ratio (instead of individual MIA components and plasma BNP) was included as an integrated marker reflecting both the MIA complex and fluid volume status. |

| Model 2 | All-cause mortality | New CVD |
|---------|---------------------|---------|
|         | Hazard Ratio (95% CI) | P     | Hazard Ratio (95% CI) | P     |
| **Unadjusted univariate** | | | | |
| ECF/ICF (0.01) | 1.18 (1.11–1.25) | <0.001 | 1.17 (1.11–1.24) | <0.001 |
| ECF/ICF ≥0.57 | 6.11 (2.41–15.49) | <0.001 | 4.02 (2.06–7.84) | <0.001 |
| ECF/dry weight (0.01 L/kg) | 1.08 (0.86–1.36) | 0.52 | 1.07 (0.90–1.27) | 0.48 |
| TBF/dry weight (0.01 L/kg) | 9.31 (0.86–1.01) | 0.09 | 0.94 (0.88–1.00) | 0.05 |
| Diabetes mellitus | 4.15 (1.77–9.71) | 0.001 | 4.88 (2.49–9.57) | <0.001 |
| Prior CVD | 8.36 (3.48–20.10) | <0.001 | 6.77 (3.44–13.34) | 0.001 |
| Plasma total CO2 (1 meq/L) | 1.01 (0.81–1.27) | 0.93 | 1.15 (0.96–1.38) | 0.14 |
| Age (10 year) | 2.00 (1.37–2.90) | <0.001 | 1.91 (1.42–2.56) | <0.001 |
| Women | 2.33 (0.99–5.47) | 0.05 | 1.52 (0.80–2.90) | 0.20 |
| Hemodialysis duration (1/ month) | 1.00 (0.98–1.01) | 0.73 | 1.00 (0.99–1.01) | 0.57 |
| Pre-dialytic SBP (10 mmHg) | 1.33 (1.12–1.58) | 0.001 | 1.32 (1.15–1.51) | <0.001 |
| Pre-dialytic DBP (10 mmHg) | 0.90 (0.60–1.37) | 0.90 | 1.00 (0.73–1.38) | 0.99 |
| Ankle brachial index (0.1) | 0.69 (0.52–0.92) | 0.01 | 0.72 (0.57–0.90) | 0.004 |
| LV ejection fraction (10%) | 0.98 (0.57–1.71) | 0.95 | 0.70 (0.46–1.06) | 0.09 |
| LV mass index (10 g/m²) | 1.00 (0.88–1.12) | 0.96 | 1.03 (0.95–1.13) | 0.44 |
| Kt/V (0.1) | 1.07 (0.89–1.31) | 0.50 | 0.98 (0.85–1.12) | 0.98 |
| Plasma intact PTH (10 pg/mL) | 0.97 (0.93–1.02) | 0.27 | 0.97 (0.94–1.00) | 0.07 |
| Serum calcium X phosphate (1) | 0.99 (0.95–1.03) | 0.57 | 1.00 (0.97–1.03) | 0.87 |
| Serum calcium (1 mg/dL) | 1.09 (0.55–2.16) | 0.81 | 1.08 (0.65–1.80) | 0.77 |
| Serum phosphate (1 mg/dL) | 0.95 (0.64–1.40) | 0.78 | 1.02 (0.78–1.35) | 0.87 |
| **Adjusted multivariate** | | | | |
| ECF/ICF (0.01) | 1.12 (1.01–1.25) | 0.03 | 1.09 (1.01–1.18) | 0.03 |
| Diabetes mellitus | 0.48 (0.11–2.10) | 0.33 | 0.80 (0.26–2.44) | 0.69 |
| Prior CVD | 7.59 (2.28–25.32) | 0.001 | 2.73 (1.10–6.75) | 0.03 |
| Age (10 year) | 1.12 (0.67–1.89) | 0.66 | 1.38 (0.94–2.03) | 0.10 |
| Pre-dialytic SBP (10 mmHg) | 1.23 (0.90–1.67) | 0.20 | 1.20 (0.98–1.47) | 0.09 |
| Ankle brachial index (0.1) | 0.78 (0.59–1.04) | 0.09 | 0.93 (0.74–1.16) | 0.49 |

Abbreviations: CVD, cardiovascular disease; ECF/ICF, extracellular fluid/intracellular fluid; LV, left ventricular; MIA, malnutrition-inflammation-arteriosclerosis; PTH, parathyroid hormone; SBP, systolic blood pressure; DBP, diastolic blood pressure; TBF, total body fluid.

doi:10.1371/journal.pone.0170272.t006
The strengths of our investigation are its prospective design, consistent definition of the ECF/ICF ratio and MIA-fluid volume components and the complete longitudinal ascertainment of all-cause mortality and new CVD. As a measure for body fluid compartment volume, MF-BIA is highly reproducible (coefficient of variation < 1.8); therefore, any biologically-important changes within the ECF and TBF, which can occur in many acute and chronic illnesses, could be detected at the bedside with this technique [14, 22]. Previous body composition studies used the ECF/TBF ratio [23, 24] or the sole ECF volume based overhydration index [8, 20, 25–27] as an indicator of the fluid volume status. However, the ECF/TBF ratio could not accurately reflect the changes within the body fluid volume; this is because a change in the ECF volume is accompanied by a simultaneous change in the ECF component of the TBF. To prevent this unidirectional change in denominator and numerator, we used the ECF/ICF ratio; this is another major strength of our investigation. Our study showed that, contrary to the ECF/ICF ratio, the ECF/TBF ratio was not an independent predictor of all-cause mortality and new CVD in the adjusted multivariate Cox analysis, which supports the superiority of the ECF/ICF ratio as risk indicator as compared with the ECF/TBF ratio. The commonly used sole ECF or TBF volume based overhydration index also have shortcoming of not accurately reflecting ICF volume based nutritional status. Our study showed that the dry weight adjusted sole ECF or TBF volume were not a significant risk factor for all-cause mortality and new CVD. The correlations of these ECF or TBF based volume markers to the MIA component and plasma BNP was also inferior as compared to the ECF/ICF ratio.

Our study nevertheless has several limitations. First, we measured the ECF/ICF ratio and MIA-fluid volume component at enrollment; these were not measured serially. Thus, it may not reflect changes over time or time-averaged exposure, although several recent studies [25–27] have shown that a single measurement of volume status by BIA can predict the long-term survival of hemodialysis patients. We also measured the pre-dialytic value of the ECF/ICF ratio to overcome the acute, uneven effect of hemodialysis ultrafiltration on ECF and ICF volumes. Second, there could be a significant inter-individual variability in the BIA-measured body composition estimate, although MF-BIA has relatively good overall agreement to the gold-standard isotope dilution techniques [28]. We speculate that our segmental BIA measurement (rather than whole-body BIA measurement) and perhaps the use of the ECF/ICF ratio value (rather than absolute ECF or ICF volume) potentially yielded more accurate results with much less inter-individual variability. Third, the levels of plasma BNP would be affected by cardiac function as well as volume status, which could decrease the significance of plasma BNP level as a volume marker. However, in this study, there was no difference in the global left ventricular systolic function as assessed by left ventricular ejection fraction between the high and low ECF/ICF ratio group. This finding implies that higher plasma BNP level, as observed in the high ECF/ICF ratio group, is more likely a result of volume excess. Fourth, this is single-center study that enrolled a relatively small numbers of hemodialysis patients, which may account for the exclusion of diabetes as a significant risk factor for both all-cause mortality and new CVD. However this may be due to the underlying association of diabetes with prior CVD and high ECF/ICF ratio that nullify the independent effect of diabetes on all-cause mortality and new CVD. A large prospective multicenter study will help confirm the causal link between the ECF/ICF ratio and all-cause mortality or CVD.

In conclusion, this study demonstrated that chronic hemodialysis patients with high ECF/ICF ratio are not only fluid overloaded, but are also malnourished and have stiff artery with more inflammation. As a novel integrated marker of fluid volume overload and malnutrition, the ECF/ICF ratio is highly-related to the MIA complex, and can be utilized as a major risk indicator for all-cause mortality and CVD in this population of patients.
Acknowledgments

This study was presented in part (as abstract form) at the Annual Meeting of the American Society of Nephrology in San Diego, CA, November 3–8, 2015. The results presented in this paper have not been published previously in whole or part, except in abstract format.

Author Contributions

Conceptualization: JRK EJK.

Formal analysis: JRK EJK.

Investigation: MJC JWS.

Methodology: MJC JWY.

Supervision: JRK.

Validation: JHL JEO YKL HJK.

Writing – original draft: EJK.

Writing – review & editing: JWN JRK.

References

1. Stenvinkel P, Heimbürger O, Lindholm B, Kaysen GA, Bergström J. Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation and atherosclerosis (MIA syndrome). Nephrol Dial Transplant. 2000; 15: 953–60 PMID: 10862630

2. Pupim LB, Caqlar K, Hakim RM, Shyr Y, Ikizler TA. Uremic malnutrition is a predictor of death independent of inflammatory status. Kidney Int. 2004; 66: 2054–60 doi: 10.1111/j.1523-1755.2004.00978.x PMID: 15496179

3. Wizemann V, Wabel P, Chamney P, Zaluska W, Moissl U, Rode C, et al. The mortality risk of overhydration in haemodialysis patients. Nephrol Dial Transplant. 2009; 24: 1574–9 doi: 10.1093/ndt/gfn707 PMID: 19131355

4. Choi MJ, Seo JW, Yoon JW, Lee SK, Kim SJ, Lee YK, et al. The malnutrition-inflammation-depression-atherosclerosis complex is associated with an increased risk of cardiovascular disease and all-cause death in chronic hemodialysis patients. Nephron Clin Pract. 2012; 122: 44–52 doi: 10.1159/000348509 PMID: 23548410

5. Qureshi AR, Alvestrand A, Divino-Filho JC, Gutierrez A, Heimbürger O, Lindholm B, et al. Inflammation, malnutrition and cardiac disease as predictors of mortality in hemodialysis patients. J Am Soc Nephrol. 2002; 13(Suppl 1): S28–S36

6. Pecoits-Filho R, Lindholm B, Stenvinkel P. The malnutrition, inflammation, and atherosclerosis (MIA) syndrome—the heart of the matter. Nephrol Dial Transplant. 2002; 17: (Suppl 11):S28–S31

7. Martola L, Barany P, Stenvinkel P. Why do dialysis patients develop a heart of stone and bone of china? Blood Purif. 2005; 23: 203–10 doi: 10.1159/000084890 PMID: 15809503

8. Hung SC, Kuo KL, Peng CH, Wu CH, Lien CY, Wang YC, et al. Volume overload correlates with cardiovascular risk factors in patients with chronic kidney disease. Kidney Int. 2014; 85: 703–9 doi: 10.1038/ki.2013.336 PMID: 24025647

9. Niebauer J, Volk HD, Kemp M, Dominguez M, Schumann RR, Rauchhaus M, et al. Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet. 1999; 353: 1838–42 doi: 10.1016/S0140-6736(99)08296-1 PMID: 1039409

10. Tycho Vuurmans JL, Boer WH, Bos WJ, Blankenstijn PJ, Koomans HA. Contribution of volume overload and angiotensin II to the increased pulse wave velocity of hemodialysis patients. J Am Soc Nephrol. 2002; 13: 177–83 PMID: 11752035

11. Achinger SG, Ayus JC. Inflammation from dialysis, can it be removed? Nephrol Dial Transplant. 2013; 28: 770–3 doi: 10.1093/ndt/gfs480 PMID: 23109559

12. Johansen KL, Dalrymple LS, Delgado C, Kaysen GA, Komak J, Grimes B, et al. Association between body composition and frailty among prevalent hemodialysis patients: A US Renal Data System special study. J Am Soc Nephrol. 2014; 25: 381–9 doi: 10.1681/ASN.2013040431 PMID: 24159867
13. Earthman C, Traughber D, Dobratz J, Howell W. Bioimpedance spectroscopy for clinical assessment of fluid distribution and body cell mass. Nutr Clin Pract. 2007; 22: 389–405 PMID: 17644693

14. Cha K, Chertow GM, Gonzalez J, Lazarus JM, Wilmore DW. Multifrequency bioelectrical impedance estimates the distribution of body water. J Appl Physiol. 1995; 79: 1316–9 PMID: 8567578

15. Canada-USA (CANUSA) Peritoneal Dialysis Study Group: Adequacy of dialysis and nutrition in continuous peritoneal dialysis: Association with clinical outcomes. J Am Soc Nephrol. 1996; 7: 198–207 PMID: 8785388

16. Yamashina A, Tomiyama H, Takeda K, Tsuda H, Arai T, Hirose K, et al. Validity, reproducibility, and clinical significance of noninvasive brachial-ankle pulse wave velocity measurement. Hypertens Res. 2002; 25: 359–64 PMID: 12135313

17. Zhu F, Schneditz D, Wang E, Martin K, Morris AT, Levin NW. Validation of changes in extracellular volume measured during hemodialysis using a segmental bioimpedance technique. ASAIO J. 1998; 44: M541–5 PMID: 9804490

18. Koo JR, Yoon JY, Joo MH, Lee HS, Oh JE, Kim SG, et al. Treatment of depression and effect of antidepressant treatment on nutritional status in chronic hemodialysis patients. Am J Med Sci. 2005; 329: 1–5 PMID: 15654172

19. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr. 1989; 2: 358–67 PMID: 2698218

20. Hur E, Usta M, Toz H, Asci G, Wabel P, Kâhvecioğlu S, et al. Effect of fluid management guided by bioimpedance spectroscopy on cardiovascular parameters in hemodialysis patients: a randomized controlled trial. Am J Kidney Dis. 2013; 61: 957–65 doi: 10.1053/j.ajkd.2012.12.017 PMID: 23415416

21. Mitch WE, Goldberg AL. Mechanisms of muscle wasting. The role of the ubiquitin-proteasome pathway. N Engl J Med. 1996; 335: 1897–905 doi: 10.1056/NEJM199612193352507 PMID: 8948566

22. Lorenzo AD, Andreoli A: Segmental bioelectrical impedance analysis. Curr Opin Clin Nutr Metab Care. 2003; 6: 551–5 doi: 10.1097/01.mco.0000087970.83880.41 PMID: 12913672

23. Tai R, Ohashi Y, Mizuiri S, Aikawa A, Sakai K, et al. Association between ratio of measured extracellular volume to expected body fluid volume and renal outcomes in patients with chronic kidney disease: a retrospective single-center cohort study. BMC Nephrol. 2014; 15: 189 doi: 10.1186/1471-2369-15-189 PMID: 25435421

24. Fan S, Sayed RH, Davenport A. Extracellular volume expansion in peritoneal dialysis patients. Int J Artif Organs. 2012; 35: 338–45 doi: 10.5301/iaoj.5000080 PMID: 22466994

25. Chazot C, Wabel P, Chamney P, Moissl U, Wieskotten S, Wizemann V, et al. Importance of normohydration for the long-term survival of haemodialysis patients. Nephrol Dial Transplant. 2012; 27: 2404–10 doi: 10.1093/ndt/gfr678 PMID: 22253067

26. Kim YJ, Jeon HJ, Kim YH, Jeon J, Ham YR, Chung S, et al. Overhydration measured by bioimpedance analysis and the survival of patients on maintenance hemodialysis: a single-center study. Kidney Res Clin Pract. 2015; 34: 212–8 doi: 10.1016/j.krcp.2015.10.006 PMID: 26779424

27. Onofriescu M, Siripoll D, Voroneanu L, Hogas S, Nistor I, Apetrii M, et al. Overhydration, Cardiac Function and Survival in Hemodialysis Patients. See comment in PubMed Commons belowPLoS One. 2015 Aug 14; 10(8):e0135691. doi: 10.1371/journal.pone.0135691 PMID: 26274811

28. Mulasi U, Kuchnia AJ, Cole AJ, Earthman CP. Bioimpedance at the Bedside: current applications, limitations, and opportunities. Nutr Clin Pract. 2015; 30: 180–93 doi: 10.1177/0884533614568155 PMID: 25613832